InvestorsHub Logo
Followers 8
Posts 314
Boards Moderated 0
Alias Born 07/21/2016

Re: None

Thursday, 05/21/2020 5:20:48 PM

Thursday, May 21, 2020 5:20:48 PM

Post# of 426469
Imagine...Vascepa as a Prophylactic 4 70M+ Americans Over Age 60

All High Risk Individuals in Fact.

Obviously assuming the trial indicates efficacy or trend towards efficacy (it is only a 2 week course after all) and so justifies a more thorough, longer course of treatment.

If they can demonstrate a reduction in inflammatory markers in such a short time then I can see Vascepa becoming not only SOC for all who test positive for COVID-19, but also for all who are at high risk for infection with potential for serious COVID-19 outcome were they to become infected - so everyone over 60(?)...all diabetics...all obese Americans. Oh Baby!

*In 2016 it was reported that over 70M Americans were age 60 and above - no current figures I found but likely the number has gone up.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News